TEVA PHARMACEUTICAL INDUSTRIES LTD Insider Trading Activity
Every SEC Form 4 insider transaction reported for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are TEVA insiders buying or selling?
In the last 12 months, TEVA PHARMACEUTICAL INDUSTRIES LTD insiders reported 0 open-market purchases ($0) and 42 sales ($92.1M) — net selling of $92.1M. Since February 2018, Trabud has recorded 241 Form 4 filings for TEVA: 5 buys ($16.5M) and 236 sells ($162.9M).
Source: SEC EDGAR Form 4
What stands out
- No TEVA PHARMACEUTICAL INDUSTRIES LTD insider made an open-market purchase in the last 12 months; the 42 reported open-market sales totaled $92.1M.
Key Statistics (February 2018 – Sep 22, 2026)
Total Form 4 filings
241
SEC EDGAR
Insider filers
30
Insider buys (5)
$16.5M
Insider sells (236)
$162.9M
Insider sentiment
Net sellingNet insider flow of $146.4M in net selling since February 2018, and $92.1M in net selling over the last 12 months.
Recent TEVA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | Brian Savage | Interim Chief Legal Officer | Sale | 7.3K | $38.85 | $285.2K | SEC ↗ |
| Sep 22, 2026 | Roberto Mignone | Director | Sale | 367.6K | $39.06 | $14.4M | SEC ↗ |
| Aug 25, 2026 | Amir Weiss | Chief Accounting Officer | Sale | 9.4K | $37.62 | $355.3K | SEC ↗ |
| Aug 25, 2026 | Ronit Satchi-Fainaro | Director | Sale | 415 | $37.25 | $15.5K | SEC ↗ |
| Aug 19, 2026 | Evan Lippman | EVP, Business Development | Sale | 18.6K | $36.57 | $680.3K | SEC ↗ |
| Aug 10, 2026 | Tal Zvi Zaks | Director | Sale | 17 | $34.87 | $592.71 | SEC ↗ |
| Aug 5, 2026 | Placid Jover | See "Remarks" | Sale | 12.8K | $34.88 | $447.4K | SEC ↗ |
| Aug 5, 2026 | Eric A Hughes | See "Remarks" | Sale | 25.6K | $34.88 | $892.1K | SEC ↗ |
| Jun 22, 2026 | Matthew Shields | EVP, Global Operations | Sale | 10.0K | $32.19 | $321.5K | SEC ↗ |
| Jun 16, 2026 | Eliyahu Sharon Kalif | EVP, Chief Financial Officer | Sale | 106.6K | $34.10 | $3.6M | SEC ↗ |
| Jun 8, 2026 | Richard D Francis | President and CEO | Sale | 6.2K | $34.35 | $211.4K | SEC ↗ |
| Jun 4, 2026 | Matthew Shields | EVP, Global Operations | Sale | 16.2K | $32.87 | $532.3K | SEC ↗ |
| May 18, 2026 | Evan Lippman | EVP, Business Development | Sale | 41.7K | $35.58 | $1.5M | SEC ↗ |
| May 18, 2026 | Eliyahu Sharon Kalif | EVP, Chief Financial Officer | Sale | 153.3K | $35.61 | $5.5M | SEC ↗ |
| May 7, 2026 | Amir Weiss | Chief Accounting Officer | Sale | 10.7K | $36.00 | $384.4K | SEC ↗ |
| May 7, 2026 | Richard Daniell | EVP, Europe Commercial | Sale | 30.0K | $35.40 | $1.1M | SEC ↗ |
| May 4, 2026 | Mark Sabag | See "Remarks" | Sale | 144.2K | $34.99 | $5.0M | SEC ↗ |
| May 4, 2026 | Christine Fox | EVP, U.S. Commercial | Sale | 21.3K | $35.31 | $750.6K | SEC ↗ |
| Mar 19, 2026 | Mark Sabag | See "Remarks" | Sale | 62.1K | $30.14 | $1.9M | SEC ↗ |
| Mar 9, 2026 | Richard D Francis | President and CEO | Sale | 20.0K | $31.67 | $634.2K | SEC ↗ |
| Mar 9, 2026 | Christine Fox | EVP, U.S. Commercial | Sale | 7.9K | $31.67 | $250.9K | SEC ↗ |
| Mar 9, 2026 | Eric A Hughes | See "Remarks" | Sale | 9.5K | $31.67 | $301.9K | SEC ↗ |
| Mar 9, 2026 | Richard Daniell | EVP, Europe Commercial | Sale | 17.3K | $31.67 | $547.7K | SEC ↗ |
| Mar 9, 2026 | Placid Jover | See "Remarks" | Sale | 14.2K | $31.67 | $448.1K | SEC ↗ |
| Mar 9, 2026 | Brian Savage | Interim Chief Legal Officer | Sale | 1.1K | $31.67 | $35.7K | SEC ↗ |
Showing the 25 most recent of 241 Form 4 filings for TEVA PHARMACEUTICAL INDUSTRIES LTD.
Most active TEVA insiders
- Richard Daniell34 filings
- Hafrun Fridriksdottir22 filings
- David Matthew Stark19 filings
- Sven Dethlefs17 filings
- Eric Drape16 filings
Ask anything about TEVA insider activity
Use Trabud's AI agent to query TEVA PHARMACEUTICAL INDUSTRIES LTD's Form 4 history in plain English — "Show me TEVA CEO purchases this year" or compare it against any other ticker.
Open the AI agentTEVA insider trading FAQ
Are TEVA PHARMACEUTICAL INDUSTRIES LTD insiders buying or selling?
In the last 12 months, TEVA PHARMACEUTICAL INDUSTRIES LTD insiders reported 0 open-market purchases ($0) and 42 sales ($92.1M) — net selling of $92.1M. Since February 2018, Trabud has recorded 241 Form 4 filings for TEVA: 5 buys ($16.5M) and 236 sells ($162.9M). Over the full record that is net selling of $146.4M.
How many insiders trade TEVA stock?
30 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for TEVA PHARMACEUTICAL INDUSTRIES LTD. The most recent filing was accepted on Sep 22, 2026.
Where does Trabud get TEVA insider trading data?
All TEVA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.